ID   NCC-GCTB3-C1
AC   CVCL_A0SS
DR   Wikidata; Q108821012
RX   PubMed=34304386;
WW   https://en.cellline.jp/product/ncc-gctb3-c1/
CC   Part of: NCC sarcoma cell line panel.
CC   Population: Japanese.
CC   Senescence: It is possible that this cell line is not immortal and has a finite life span (personal communication of Kondo T.).
CC   Doubling time: 26 hours (PubMed=34304386).
CC   Sequence variation: Mutation; HGNC; 4764; H3-3A; Simple; p.Gly35Trp (c.103G>T) (G34W); Zygosity=Heterozygous (PubMed=34304386).
CC   Omics: SNP array analysis.
CC   Derived from site: In situ; Bone, proximal tibia; UBERON=UBERON_0008772.
ST   Source(s): PubMed=34304386
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 13
ST   D16S539: 9
ST   D21S11: 30
ST   D5S818: 10,14
ST   D7S820: 8,11
ST   TH01: 6
ST   TPOX: 8
ST   vWA: 17
DI   NCIt; C4304; Malignancy in giant cell tumor of bone
DI   ORDO; Orphanet_363976; Giant cell tumor of bone
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   20Y
CA   Cancer cell line
DT   Created: 23-09-21; Last updated: 30-01-24; Version: 5
//
RX   PubMed=34304386; DOI=10.1007/s13577-021-00579-z;
RA   Yoshimatsu Y., Noguchi R., Tsuchiya R., Ono T., Sin Y., Akane S.,
RA   Sugaya J., Mori T., Fukushima S., Yoshida A., Kawai A., Kondo T.;
RT   "Establishment and characterization of novel patient-derived cell
RT   lines from giant cell tumor of bone.";
RL   Hum. Cell 34:1899-1910(2021).
//